- Home
- VRTX
as 05-23-2025 4:00pm EST
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 115.6B | IPO Year: | 1991 |
| Target Price: | $512.54 | AVG Volume (30 days): | 2.1M |
| Analyst Decision: | Buy | Number of Analysts: | 26 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $377.85 - $519.88 | Next Earning Date: | 05-05-2025 |
| Revenue: | $11,099,700,000 | Revenue Growth: | 8.98% |
| Revenue Growth (this year): | 10.36% | Revenue Growth (next year): | 10.61% |
Stock Insider Trading Activity of Vertex Pharmaceuticals Incorporated (VRTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | May 15 '25 | Sell | $424.69 | 52 | $22,083.88 | 23,281 | |
| Bhatia Sangeeta N. | VRTX | Director | May 1 '25 | Sell | $505.86 | 400 | $202,344.00 | 4,831 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 13 '25 | Sell | $510.00 | 3,231 | $1,647,810.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 10 '25 | Sell | $499.99 | 3,242 | $1,620,967.58 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 10 '25 | Sell | $500.00 | 3,231 | $1,615,500.00 | 23,281 | |
| WAGNER CHARLES F JR | VRTX | EVP & Chief Financial Officer | Mar 10 '25 | Sell | $500.00 | 3,298 | $1,649,000.00 | 51,671 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Mar 4 '25 | Sell | $485.49 | 4,058 | $1,970,118.42 | 51,239 | |
| ALTSHULER DAVID | VRTX | EVP, Chief Scientific Officer | Mar 3 '25 | Sell | $490.00 | 3,231 | $1,583,190.00 | 23,281 | |
| Tatsis Ourania | VRTX | EVP, Chief Reg. & Quality Off. | Feb 26 '25 | Sell | $475.34 | 530 | $251,930.20 | 51,239 | |
| Atkinson Edward Morrow III | VRTX | EVP, Chief Technical Ops. Off. | Feb 26 '25 | Sell | $475.34 | 2,650 | $1,259,651.00 | 19,352 |
Latest Vertex Pharmaceuticals Incorporated News
VRTX Breaking Stock News: Dive into VRTX Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
2 Monster Growth Stocks to Buy and Hold for 10 Years
MT Newswires
3 days ago
Argus Adjusts Price Target on Vertex Pharmaceuticals to $525 From $550
Argus Research
3 days ago
Analyst Report: Vertex Pharmaceuticals, Inc.
Argus Research
3 days ago
Market Digest: AIG, HST, PSA, VRTX
Motley Fool
5 days ago
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Motley Fool
6 days ago
CRISPR Therapeutics Stock Could Double Your Money, According to Wall Street. Is It Time to Buy?
StockStory
7 days ago
VRTX Q1 Earnings Call: New Product Launches and Pipeline Progress Amid Revenue Miss
The Wall Street Journal
7 days ago
The Top Corporate Board Directors
Compare VRTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VRTX Vertex Pharmaceuticals Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.